Scalable Culturing of Primary Human Glioblastoma Tumor-Initiating Cells with a Cell-Friendly Culture System

Glioblastoma is the most aggressive and deadly brain cancer. There is growing interest to develop drugs that specifically target to glioblastoma tumor-initiating cells (TICs). However, the cost-effective production of large numbers of high quality glioblastoma TICs for drug discovery with current cell culturing technologies remains very challenging. Here, we report a new method that cultures glioblastoma TICs in microscale alginate hydrogel tubes (or AlgTubes). The AlgTubes allowed long-term culturing (~50 days, 10 passages) of glioblastoma TICs with high growth rate (~700-fold expansion/14 days), high cell viability and high volumetric yield (~3.0 × 108 cells/mL) without losing the stem cell properties, all offered large advancements over current culturing methods. This method can be applied for the scalable production of glioblastoma TICs at affordable cost for drug discovery.

[1]  N. Warrington,et al.  Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions , 2015, Oncotarget.

[2]  A. Boyd,et al.  Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines , 2015, Anatomy & cell biology.

[3]  Jacques Haiech,et al.  Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells , 2015, PloS one.

[4]  Y. Lei,et al.  Scalable Production of Glioblastoma Tumor-initiating Cells in 3 Dimension Thermoreversible Hydrogels , 2016, Scientific Reports.

[5]  Shang-Tian Yang,et al.  Cell-Based Assays in High-Throughput Screening for Drug Discovery , 2012 .

[6]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[7]  J. Tabernero,et al.  Cancer: A precision approach to tumour treatment , 2017, Nature.

[8]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[9]  S. Weiss,et al.  Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens , 2009, Stem cells.

[10]  Kristopher L. Nazor,et al.  Increased Risk of Genetic and Epigenetic Instability in Human Embryonic Stem Cells Associated with Specific Culture Conditions , 2015, PloS one.

[11]  A. Vescovi,et al.  Evidence for label-retaining tumour-initiating cells in human glioblastoma. , 2011, Brain : a journal of neurology.

[12]  Wee Keat Chong,et al.  Time-resolved video analysis and management system for monitoring cardiomyocyte differentiation processes and toxicology assays. , 2014, Biotechnology journal.

[13]  Suzanne S Farid,et al.  Human pluripotent stem cell-derived products: Advances towards robust, scalable and cost-effective manufacturing strategies , 2014, Biotechnology journal.

[14]  W. Janzen,et al.  High Throughput Screening , 2016, Methods in Molecular Biology.

[15]  Vladimir Mironov,et al.  Tissue spheroid fusion‐based in vitro screening assays for analysis of tissue maturation , 2010, Journal of tissue engineering and regenerative medicine.

[16]  Melissa A. Kinney,et al.  Hydrodynamic modulation of pluripotent stem cells , 2012, Stem Cell Research & Therapy.

[17]  R. McKay,et al.  Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. , 2014, Cell stem cell.

[18]  D. Kehoe,et al.  Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. , 2010, Tissue engineering. Part A.

[19]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[20]  David V. Schaffer,et al.  A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation , 2013, Proceedings of the National Academy of Sciences.

[21]  D. Steindler,et al.  Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.

[22]  Yuguo Lei,et al.  Developing Defined and Scalable 3D Culture Systems for Culturing Human Pluripotent Stem Cells at High Densities , 2014, Cellular and molecular bioengineering.

[23]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[24]  Jin-xiang Cheng,et al.  How powerful is CD133 as a cancer stem cell marker in brain tumors? , 2009, Cancer treatment reviews.

[25]  S. Bidlingmaier,et al.  The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells , 2008, Journal of Molecular Medicine.

[26]  J. Loring,et al.  The tumorigenic potential of pluripotent stem cells: What can we do to minimize it? , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

[27]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[28]  R. Lahesmaa,et al.  Genetic and epigenetic stability of human pluripotent stem cells , 2012, Nature Reviews Genetics.

[29]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[30]  A. Quiñones‐Hinojosa,et al.  Neurosphere Assays: Growth Factors and Hormone Differences in Tumor and Nontumor Studies , 2006, Stem cells.

[31]  N. Benvenisty,et al.  Genome maintenance in pluripotent stem cells , 2014, The Journal of cell biology.

[32]  Catarina Brito,et al.  Process engineering of human pluripotent stem cells for clinical application. , 2012, Trends in biotechnology.

[33]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[34]  Sabine Borwege,et al.  PNIPAAm-co-Jeffamine® (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells. , 2017, Biomaterials.

[35]  T. Kondo,et al.  Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[37]  S. Ansari,et al.  Isolation and expansion of human glioblastoma multiforme tumor cells using the neurosphere assay. , 2011, Journal of visualized experiments : JoVE.

[38]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[39]  Todd C McDevitt,et al.  The multiparametric effects of hydrodynamic environments on stem cell culture. , 2011, Tissue engineering. Part B, Reviews.

[40]  Tom Mikkelsen,et al.  High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. , 2015, ACS medicinal chemistry letters.

[41]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[42]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[43]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[44]  R. McKay,et al.  Developmental insights from early mammalian embryos and core signaling pathways that influence human pluripotent cell growth and differentiation. , 2014, Stem cell research.

[45]  P. Itsykson,et al.  Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension , 2010, Nature Biotechnology.

[46]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[47]  Jae-Geun Yoon,et al.  High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells , 2012, Oncotarget.

[48]  Andreas Fouras,et al.  Flow Characterization of a Spinner Flask for Induced Pluripotent Stem Cell Culture Application , 2014, PloS one.

[49]  O. Chinot,et al.  Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. , 2014, Experimental cell research.

[50]  R. Gilbertson,et al.  Making a tumour's bed: glioblastoma stem cells and the vascular niche , 2007, Nature Reviews Cancer.

[51]  C. Beier,et al.  Chemoresistance of glioblastoma cancer stem cells - much more complex than expected , 2011, Molecular Cancer.

[52]  D. Mooney,et al.  Alginate: properties and biomedical applications. , 2012, Progress in polymer science.

[53]  Dong-Sup Lee,et al.  Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas , 2008, Laboratory Investigation.

[54]  Mark Bernstein,et al.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.

[55]  Harikrishna Narasimhan,et al.  Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity , 2015, Nature Communications.

[56]  Diana Nada Caterina Massai,et al.  Progress and challenges in large-scale expansion of human pluripotent stem cells , 2017 .